Isolated Angioedema Without Urticaria in a Patient Taking an ACE Inhibitor or Angiotensin Receptor Blocker
Clinical Scenario
This protocol applies to isolated angioedema that presents without urticaria in a patient taking an ACE inhibitor or an angiotensin receptor blocker (ARB). Swelling is characteristically localized to the head, neck, lips, mouth, tongue, larynx, pharynx, and subglottal regions.
Up to 68% of cases of isolated angioedema without urticaria are attributable to an ACE inhibitor. The management of ARB-related angioedema follows the same clinical approach as ACE inhibitor angioedema.
Management Priority
When specific signs of airway compromise are present, immediate airway management is the critical first priority. The full protocol defines the precise clinical presentations that require this intervention and details the complete management pathway.
Full indications, clinical decision points, and next steps are in the structured protocol below.
References
- Clinically, ACE inhibitor angioedema presents without urticaria.
- Up to 68% of cases of isolated angioedema are due to an ACE inhibitor.
- Edema is often localized to the head, neck, lips, mouth, tongue, larynx, pharynx, and subglottal regions.
- The management of patients with ARB angioedema is identical to that of patients with ACE inhibitor angioedema.
- Immediately intubate patients with stridor, accessory muscle use, or drooling of saliva.
- Additional indications for intubation, based upon retrospective series, include tongue edema and edema of the floor of the mouth.
- Intubate patients presenting with respiratory distress, stridor, drooling, tongue edema, or significant edema of the floor of the mouth.
View source ↗